Successful clinical translation of the fimaVACC technology

Posted on May 3, 2019

Oslo (Norway), 2 May 2019 – PCI Biotech (OSE: PCIB), a cancer focused clinical-stage company developing innovative therapeutics that address significant unmet medical needs today announced that the final immune response results from the fimaVacc Phase I study in healthy volunteers indicate a clear enhancement of both CD8 and CD4 T-cell responses and an improved […]

Invitation to first quarter 2019 result presentation

Posted on Apr 30, 2019

Oslo, Norway, 30 April 2019 – PCI Biotech invites to a presentation of the company’s first quarter 2019 result on Wednesday 8 May 2019 at Oslo Cancer Cluster Innovation Park. Time: Wednesday 8 May, 08:30am – 09:30am CEST (local time). Venue: Jónas Einarsson aud. (2nd floor, entrance 2B), Oslo Cancer Cluster Innovation Park, Ullernchausséen 64, […]

Annual Report 2018

Posted on Apr 9, 2019

Oslo, Norway, April 9, 2019 – The Board of Directors of PCI Biotech Holding ASA has approved the Annual Report 2018 and the report is attached. The Annual Report 2018 is also available on the company’s website www.pcibiotech.com. For further information, please contact:              PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo        Per Walday, CEO, pw@pcibiotech.no, […]